Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

24 de julio de 2017 actualizado por: Novo Nordisk A/S

An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B

This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

The aim of the trial is to evaluate the safety and efficacy of NNC-0156-0000-0009 (nonacog beta pegol) during surgical procedures in patients with haemophilia B.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

13

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Alemania
      • Bonn, Alemania, 53127
        • Novo Nordisk Investigational Site
      • Duisburg, Alemania, 47051
        • Novo Nordisk Investigational Site
      • Giessen, Alemania, 35392
        • Novo Nordisk Investigational Site
      • Hannover, Alemania, 30625
        • Novo Nordisk Investigational Site
  • Austria
      • Wien, Austria, 1090
        • Novo Nordisk Investigational Site
  • España
      • Madrid, España, 28046
        • Novo Nordisk Investigational Site
      • Valencia, España, 46026
        • Novo Nordisk Investigational Site
  • Estados Unidos
    • California
      • Los Angeles, California, Estados Unidos, 90027
        • Novo Nordisk Investigational Site
      • San Francisco, California, Estados Unidos, 94143
        • Novo Nordisk Investigational Site
    • District of Columbia
      • Washington, D.C., District of Columbia, Estados Unidos, 20007
        • Novo Nordisk Investigational Site
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Novo Nordisk Investigational Site
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Novo Nordisk Investigational Site
    • New York
      • Syracuse, New York, Estados Unidos, 13210
        • Novo Nordisk Investigational Site
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Novo Nordisk Investigational Site
  • Francia
      • Kremlin-Bicêtre, Francia, 94270
        • Novo Nordisk Investigational Site
      • Lyon, Francia, 69003
        • Novo Nordisk Investigational Site
  • Grecia
      • Athens, Grecia, GR-11527
        • Novo Nordisk Investigational Site
  • Italia
      • Firenze, Italia, 50134
        • Novo Nordisk Investigational Site
      • Milano, Italia, 20124
        • Novo Nordisk Investigational Site
  • Japón
      • Kashihara-shi, Nara, Japón, 634 8522
        • Novo Nordisk Investigational Site
      • Kawasaki-shi, Kanagawa, Japón, 216-8511
        • Novo Nordisk Investigational Site
      • Nagoya-shi, Aichi, Japón, 466 8560
        • Novo Nordisk Investigational Site
      • Nishinomiya-shi, Japón, 663 8051
        • Novo Nordisk Investigational Site
      • Suginami-ku, Tokyo, Japón, 167 0035
        • Novo Nordisk Investigational Site
      • Tokyo, Japón, 108-8639
        • Novo Nordisk Investigational Site
  • Macedonia, la ex República Yugoslava de
      • Skopje, Macedonia, la ex República Yugoslava de, 1000
        • Novo Nordisk Investigational Site
  • Malasia
      • Kuala Lumpur, Malasia, 50400
        • Novo Nordisk Investigational Site
  • Pavo
      • Ankara, Pavo, 06500
        • Novo Nordisk Investigational Site
      • Kayseri, Pavo, 38010
        • Novo Nordisk Investigational Site
      • Konya, Pavo, 42090
        • Novo Nordisk Investigational Site
  • Países Bajos
      • Utrecht, Países Bajos, 3584 CX
        • Novo Nordisk Investigational Site
  • Reino Unido
      • Basingstoke, Reino Unido, RG24 9NA
        • Novo Nordisk Investigational Site
      • Cardiff, Reino Unido, CF14 4XW
        • Novo Nordisk Investigational Site
      • London, Reino Unido, NW3 2QG
        • Novo Nordisk Investigational Site
      • London, Reino Unido, SE1 7EH
        • Novo Nordisk Investigational Site
      • Manchester, Reino Unido, M13 9WL
        • Novo Nordisk Investigational Site
      • Oxford, Reino Unido, OX3 7LJ
        • Novo Nordisk Investigational Site
  • Rumania
    • Timis
      • Timisoara, Timis, Rumania, 300011
        • Novo Nordisk Investigational Site
  • Sudáfrica
    • Gauteng
      • Parktown Johannesburg, Gauteng, Sudáfrica, 2193
        • Novo Nordisk Investigational Site
  • Tailandia
      • Bangkok, Tailandia, 10400
        • Novo Nordisk Investigational Site
  • Taiwán
      • Taipei, Taiwán, 100
        • Novo Nordisk Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

13 años a 70 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  • Patients with haemophilia B with a FIX activity below or equal to 2%
  • Male patients with moderately severe or severe congenital haemophilia B with a FIX activity below or equal to 2% according to medical records
  • History of at least 150 exposure days to other FIX products
  • Scheduled major surgery

Exclusion Criteria:

  • Known history of FIX (coagulation factor nine) inhibitors based on existing medical records, laboratory report reviews and patient and LAR (legal acceptable representative) interviews
  • Current FIX (coagulation factor nine) inhibitors above or equal to 0.6 Bethesda Units (central laboratory)
  • Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)
  • ALT (alanine aminotransferase) 3 times the upper limit of normal reference ranges at screening (central laboratory)
  • Immune modulating or chemotherapeutic medication

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Patients enrolled in trial
New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
Droga: nonacog beta pegol
The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
Otros nombres:
  • NNC-0156-0000-0009

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale (Excellent, Good, Moderate, Poor)
Periodo de tiempo: At the day of surgery

Haemostatic effect during surgery was evaluated immediately after surgery (last stitch) using a fourpoint response scale:

- Four-point response scale: Excellent, good, moderate, poor. The evaluation was done by the surgeon, anaesthesiologist and/or investigator based on experience as follows:

  1. Excellent: Better than expected/predicted in this type of procedure.
  2. Good: As expected in this type of procedure.
  3. Moderate: Less than optimal for the type of procedure but haemostatic response maintained without change of treatment regimen.
  4. Poor: Bleeding due to inadequate therapeutic response with adequate dosing, change of regimen required.
At the day of surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Consumption of NNC-0156-0000-0009 (U/kg Body Weight)
Periodo de tiempo: During surgery (the time from knife to skin until last stitch) and post-operative period (day 1 to day 13)
Mean consumption of nonacog beta pegol (U/kg) used for treatment per patient before surgery, during surgery (the time from knife to skin until last stitch) and post-operative period.
During surgery (the time from knife to skin until last stitch) and post-operative period (day 1 to day 13)
Transfusion Requirements (Fulfilling Transfusion Criteria)
Periodo de tiempo: during surgery (the time from knife to skin until last stitch) and post-operative period (day 1 to day 13)
Mean quantity of transfusion during surgery (the time from knife to skin until last stitch) and the postoperative period (Day 1-13).None of the patients required transfusions beyond Day 6 hence no values presented for days 7-13.
during surgery (the time from knife to skin until last stitch) and post-operative period (day 1 to day 13)
Haemoglobin Pre- and Post-surgery Start
Periodo de tiempo: 0, 1 hour, 24 hours.
The mean pre-surgery and post surgery haemoglobin level.
0, 1 hour, 24 hours.
Incidence of Adverse Events (AEs)
Periodo de tiempo: during the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) until 4 weeks after post-operative period (day 1 to day 13)
The number of adverse events per patient years of exposure, reported during the trial period. Number is the only available option here, the data presented are rate of AEs.
during the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) until 4 weeks after post-operative period (day 1 to day 13)
Incidence of Serious Adverse Events (SAE)
Periodo de tiempo: During the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) until 4 weeks after post-operative period (day 1 to day 13)
The number of serious adverse events per patient years of exposure, reported during the trial period. Number is the only available option here, the data presented are rate of AEs.
During the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) until 4 weeks after post-operative period (day 1 to day 13)
Incidence of Inhibitors Against FIX (Coagulation Factor Nine)
Periodo de tiempo: During the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) and every 4 weeks after post-operative period (day 1 to day 13)
Number of patients with inhibitory antibodies
During the trial period (2-8 weeks prior to day of surgery (transferred subjects) or 2-4 weeks prior to day of surgery (new subjects) and every 4 weeks after post-operative period (day 1 to day 13)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Novo Nordisk A/S

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

  • Escobar M, Colberg T, Karim F, Caliskan U, Chowdary P, Giangrande P, Giermasz A, Mancuso ME, Serban M, Tsay W, Zak M and Mahlangu J. Perioperative hemostatic management of major surgery in hemophilia B with long-acting recombinant glycopegylated factor IX: results from the paradigm™3 clinical trial. Journal of Thrombosis and Haemostasis (Abstracts) 2015; 13 (Supplement S2): 1-997 [OR348]

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de junio de 2012

Finalización primaria (Actual)

1 de diciembre de 2013

Finalización del estudio (Actual)

1 de diciembre de 2013

Fechas de registro del estudio

Enviado por primera vez

30 de junio de 2011

Primero enviado que cumplió con los criterios de control de calidad

30 de junio de 2011

Publicado por primera vez (Estimar)

1 de julio de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de agosto de 2017

Última actualización enviada que cumplió con los criterios de control de calidad

24 de julio de 2017

Última verificación

1 de julio de 2017

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • NN7999-3773
  • 2010-023070-40 (Número EudraCT)
  • U1111-1121-4554 (Otro identificador: WHO)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir